Biopharmaceutical companies continue to seek growth opportunities amidst increased focus on specialty pharmaceuticals. Increasing investment across the industry has been seen in scientific innovation (Immuno-oncology, Immunology), rare diseases, precision medicine, new technologies (ADCs, BsAbs, Cell & Gene Therapy), translational medicine and AI- driven drug discovery.

The Biopharmaceutical and MedTech M&A landscapes are shaped by investment cycles, based on macroeconomic factors. However, deal activity continues to drive innovation for new products and operational performance improvement.

Our team brings significant operating and consulting experience across the Biopharmaceutical, MedTech and Private Equity sectors. We advise and partner with clients to assist them in achieving their goals, and performance improvement across the investment continuum from strategy through operational implementation.

We can help with:

We assist various Life Science companies and their investors, including:

• Biopharmaceutical Companies
• MedTech Companies (Devices and Diagnostics)
• Pharmaceutical Services Organizations (CMOs, CDMOs, CROs)
• Board of Directors
• PE Firms
• Activist Investors
• Law Firms (Restructuring, Bankruptcy, Disputes & Investigations, Expert Witness Reports and Testimony)
• Unsecured Creditor Committees